RxDoctor Payments DataLook up a doctor →

Amy Seeber, MD

Internal Medicine · El Dorado, KSNPI 1962421982

Payments from drug & device makers

$7,323in general payments, 2019–2025

Across 449 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$934
  • AbbVie$833
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$715
  • AstraZeneca$707
  • Amgen$481
  • Lilly USA, LLC$473
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$7,316100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,323 in reported general payments places this provider in the 90th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$160,794
Medicare patients
539
Services billed
2,602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban334$191,201
OzempicSemaglutide136$152,409
JardianceEmpagliflozin134$121,394
MounjaroTirzepatide56$59,844
XareltoRivaroxaban83$52,716
JanuviaSitagliptin Phosphate75$44,181
Invega SustennaPaliperidone Palmitate12$44,126
FarxigaDapagliflozin Propanediol70$40,025
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$25,600
GemtesaVibegron44$20,624
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog68$17,807
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$16,837
OxycontinOxycodone Hcl11$16,393
RexultiBrexpiprazole22$16,014
Potassium Chloride575$15,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$418$191,201334 claims
Novo NordiskOzempic$934$152,409136 claims
Boehringer IngelheimJardiance, Tradjenta$143$136,820163 claims
Johnson & JohnsonXarelto, Invega Sustenna$129$96,84295 claims
Lilly USA, LLCMounjaro$473$59,84456 claims
AstraZenecaFarxiga, Breztri Aerosphere$707$56,86288 claims
MerckJanuvia, Belsomra$89$51,592102 claims
GSKTrelegy Ellipta, Breo Ellipta$100$32,80851 claims
AbbVieVraylar, Linzess$833$24,14328 claims
Sumitomo Pharma America, Inc.Gemtesa$252$20,62444 claims
Otsuka America Pharmaceutical, Inc.Rexulti$131$16,01422 claims
NovartisEntresto$40$14,96152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in El Dorado

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →